Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Epigenetic Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BRD4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BRD4 Bromodomains (BD1/BD2) and NET domain / Full-Length / Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Including clinically relevant variants (e.g., rs35177876). |
View BRD4 Products |
| Gene Delivery | BRD4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Sequence Verified. |
View BRD4 Products |
| Benchmark Ab | Anti-BRD4 Recombinant Antibody (ChIP/IF/Western Grade) Recombinant positive control for target engagement. |
View BRD4 Products |
| Validator | BRD4 siRNA Set For knockdown verification. |
View BRD4 Products |
| Related Target A | BRD2 BET family selectivity counter-screening. |
View BRD2 Products |
| Related Target B | MYC Downstream oncogenic driver validation. |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| BET Family Selectivity | BRD2/3/4/T homolog panel proteins strictly verified by mass spec. |
| PROTAC Ternary Complex Validation | High-purity soluble domains optimized for SPR and TR-FRET assays. |
| Lack of Controls | Clinical Benchmark small molecules and antibodies included. |
| False Positives | Validated siRNA included for specificity checks. |
BRD4 Protein Domains and Key Mutations
BRD4 contains two N-terminal bromodomains (BD1 and BD2) that recognize acetylated lysines on histones, and a C-terminal NET domain (a unique extraterminal domain) involved in transcriptional regulation. Key mutations documented in UniProt (O60885) include dbSNP:rs35177876 (uncertain significance) and variants found in patients with neurodevelopmental syndromes (likely pathogenic). TarMart offers recombinant proteins covering these domains and mutations for functional studies and drug screening.
Live BRD4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BRD4 therapeutics has rapidly evolved from pan-BET inhibitors to highly selective PROTACs (protein degraders) and BD1/BD2 domain-selective molecules. As first-generation small molecules face dose-limiting toxicities, the next wave of R&D is focused on precision degradation to improve the therapeutic index in hematological malignancies and solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC Degrader | Arvinas, Pelago | Prostate Cancer, AML | Ternary Complex Assay (Need ultra-pure BD1/BD2 domains) |
| Small Molecule Inhibitor | Zenith Epigenetics, BMS | Solid Tumors | Selectivity Assay (Need Homolog Panel BRD2/3/T) |
| Dual Inhibitors (e.g., BRD4/PI3K) | Various biotechs | Refractory Tumors | Off-target screening (Need diverse pathway proteins) |